BIO-Europe Spring 2019: Adrenomed’s Hein on sepsis and beyond.
“We don’t want sepsis to be the number one killer in the USA’s ICU anymore. We want to substantially cut the mortality rate” said Adrenomed CBO Dr. Frauke Hein about the company’s mission and its first-in-class antibody Adrecizumab during a video interview with Mike Ward of Pharma intelligence | informa in at the recent BIO-Europe Spring in Vienna.
Watch the whole interview.
